Guardant Health Inc
Închisă
SectorSănătate
157.41 -0.3
Rezumat
Modificarea prețului
24h
Minim
156.16
Maxim
158.93
Venit | -8.1M -120M |
|---|---|
Vânzări | 33M 335M |
EPS | -0.89 |
Marjă de profit | -35.866 |
Angajați | 2,490 |
EBITDA | -8.1M -109M |
Următoarele câștiguri | 28 oct. 2026 |
|---|
Capitalizare de piață | 2.4B 22B |
|---|---|
Deschiderea anterioară | 157.71 |
Închiderea anterioară | 157.41 |
Sentimentul știrilor
By Acuity
50%
50%
136 / 339 Clasament în Healthcare
Guardant Health Inc Grafic
Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.
Știri relevante
Comparație
Modificare preț
Guardant Health Inc Așteptări
Sentiment
By Acuity
136 / 339 Clasament în Sănătate
Sentimentul știrilor
Neutral
Volatilitate
Sub medie
Volumul știrilor (RCV)
Medie
Date financiare
Cheltuieli de vânzare și administrare
Cheltuieli de exploatare
Profit pre-impozitare
Vânzări
Costul vânzărilor
Profit brut din vânzări
Cheltuieli cu dobânzile pe datorie
EBITDA
Profit operațional
$
Despre Guardant Health Inc
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.